In vitro targeted photodynamic therapy with a pyropheophorbide-a conjugated inhibitor of prostate-specific membrane antigen

Prostate

Volumn 69, Issue 6, 2009, Pages 585-594

  Liu, Tiancheng ^a   Wu, Lisa Y ^a   Choi, Joseph K ^a   Berkman, Clifford E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Prostate cancer; PSMA; Pyropheophorbide a; Targeted photodynamic therapy

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; CHLOROPHYLL; DNA; DRUG DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PYROPHEOPHORBIDE A;

APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN LNCAP; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DNA FRAGMENTATION; HUMAN; HUMAN CELL; IMAGING; IMMUNOFLUORESCENCE; IN VITRO STUDY; NICK END LABELING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; DRUG ANTAGONISM; DRUG EFFECT; MALE; METHODOLOGY; PHOTOCHEMOTHERAPY; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CHLOROPHYLL; DNA FRAGMENTATION; DNA, NEOPLASM; HUMANS; MALE; PHOTOCHEMOTHERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 65549157938     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20909     Document Type: Article

References (67)

1. Kessel D. Photodynamic therapy: From the beginning. Photodiagnosis Photodynamic Ther 2004;1(1):3-7.
2. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res 2003;23(5A):3591-3600. (Pubitemid 37474301)
3. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001;74(5):656-669.
4. Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 2004;47(16):3897-3915. (Pubitemid 38970949)
5. Allison RR, DownieGH,Cuenca R,HuXH, Childs CJ, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis Photodynamic Ther 2004;1(1):27-42. (Pubitemid 40311381)
6. Nyman ES, Hynninen PH. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B Biol 2004;73(1):1-28. (Pubitemid 38145763)
7. Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A, Engesaeter BO, Angell-Petersen E, Warloe T, Frandsen N, Hogset A. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc 2005;218(Pt 2):133-147. (Pubitemid 40655323)
8. Sharman WM, van Lier JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 2004;56(1):53-76. (Pubitemid 38045424)
9. Stefflova K, Chen J, Zheng G. Killer beacons for combined cancer imaging and therapy. Curr Med Chem 2007;14(20):2110-2125. (Pubitemid 47578152)
10. Johansson A, Axelsson J, Andersson-Engels S, Swartling J. Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate. Med Phys 2007;34(11):4309-4321. (Pubitemid 350029653)
11. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate 1997;32(2):140-148. (Pubitemid 27280358)
12. Slovin SF. Targeting novel antigens for prostate cancer treatment: Focus on prostate-specific membrane antigen. Expert Opin Ther Targets 2005;9(3):561-570.
13. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5(10):2674-2681. (Pubitemid 29493938)
14. Chang SS, Reuter VE, Heston WD, Gaudin PB. Department of Urologic Surgery VUMCNTUSA. Comparison of antiprostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001;57(6):1179-1183.
15. Rosenthal SA, Haseman MK, Polascik TJ, Division of Radiation Oncology RAoSMGICUSA. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 2001;7(1):27-37.
16. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-4601. (Pubitemid 46224061)
17. Chu TC, Shieh F, Lavery LA, Levy M, Richards-Kortum R, Korgel BA, Ellington AD. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron 2006;21(10):1859-1866.
18. Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C, Kiselyuk A, Teply B, Eng G, Langer R. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem 2005;77(17):5453-5459. (Pubitemid 41266036)
19. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005;11(11):4022-4028.
20. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22(8):969-976.
21. Guilarte TR, McGlothan JL, Foss CA, Zhou J, Heston WD, Kozikowski AP, Pomper MG, Department of Environmental Health Sciences JHSoPHBMDUSA. Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography. Neurosci Lett 2005;387(3):141-144.
22. Humblet V, Lapidus R, Williams LR, Tsukamoto T, Rojas C, Majer P, Hin B, Ohnishi S, De Grand AM, Zaheer A, Renze JT, Nakayama A, Slusher BS, Frangioni JV. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 2005;4(4):448-462. (Pubitemid 43143785)
23. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25(5):540-547. (Pubitemid 350002961)
24. Pomper MG, Musachio JL, Zhang J, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF, Kozikowski AP. 11C-MCG: Synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 2002;1(2):96-101.
25. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology 2005;65(5 Suppl):9-16, discussion 17.
26. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44(4):610-617.
27. Tsukamoto T, Wozniak KM, Slusher BS. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007;12(17-18):767-776. (Pubitemid 47362787)
28. Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2008;7(6):974-982.
29. Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008;51(15):4504-4517.
30. Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG. N-[N-[(S)-1,3-Dicarboxypropyl] carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin Cancer Res 2008;14(10):3036-3043.
31. Tasch J, Gong M, Sadelain M, Heston WD, Department of Urology MHMS-KCCNYNYUSA. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy? Crit Rev Immunol 2001;21:1-3.
32. Salit RB, Kast WM, Velders MP. Ins and outs of clinical trials with peptide-based vaccines. Front Biosci 2002;7:e204-e213.
33. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62(20):5807-5812. (Pubitemid 35204739)
34. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53(1):9-23.
35. Liu T, Wu LY, Kazak M, Berkman CE. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 2008;68(9):955-964.
36. Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD. MultiepitopeHER2targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res 2005;65(14):6371-6379. (Pubitemid 40994424)
37. Sun X, Leung WN. Photodynamic therapy with pyropheophorbide- a methyl ester in human lung carcinoma cancer cell: Efficacy, localization and apoptosis. Photochem Photobiol 2002;75(6):644-651.
38. Stefflova K, Li H, Chen J, Zheng G. Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent. Bioconjug Chem 2007;18(2):379-388. (Pubitemid 46493508)
39. Wu LY, Anderson MO, Toriyabe Y, Maung J, Campbell TY, Tajon C, Kazak M, Moser J, Berkman CE. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 2007;15(23):7434-7443. (Pubitemid 47539133)
40. Anderson MO, Wu LY, Santiago NM, Moser JM, Rowley JA, Bolstad ES, Berkman CE. Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 2007;15(21):6678-6686. (Pubitemid 47385247)
41. Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 2004;12(18):4969-4979. (Pubitemid 39164405)
42. Liu T, Toriyabe Y, Berkman CE. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 2006;49(2):251-255. (Pubitemid 44416227)
43. Willingham MC. Cytochemical methods for the detection of apoptosis. J Histochem Cytochem 1999;47(9):1101-1110.
44. Allen RT, Hunter WJ III, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods 1997;37(4):215-228. (Pubitemid 27380389)
45. Matroule JY, Carthy CM, Granville DJ, Jolois O, Hunt DW, Piette J. Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene 2001;20(30):4070-4084. (Pubitemid 32681612)
46. Inoue H, Kajimoto Y, Shibata MA, Miyoshi N, Ogawa N, Miyatake S, Otsuki Y, Kuroiwa T. Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy. J Neurooncol 2007;83(3):223-231. (Pubitemid 46952232)
47. Yslas EI, Durantini EN, Rivarola VA. Zinc-(II) 2,9,16,23-tetrakis (methoxy) phthalocyanine: Potential photosensitizer for use in photodynamic therapy in vitro. Bioorg Med Chem 2007;15(13):4651-4660.
48. Sharma S, Dube A, Bose B, Gupta PK. Pharmacokinetics and phototoxicity of purpurin-18 in human colon carcinoma cells using liposomes as delivery vehicles. Cancer Chemother Pharmacol 2006;57(4):500-506. (Pubitemid 43087593)
49. Hsieh YJ, Wu CC, Chang CJ, Yu JS. Subcellular localization of Photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: When plasma membranes are the main targets. J Cell Physiol 2003;194(3):363-375.
50. Alvarez-Gonzalez R, Spring H, Muller M, Burkle A. Selective loss of poly(ADP-ribose) and the 85-kDa fragment of poly-(ADP-ribose) polymerase in nucleoli during alkylation-induced apoptosis of HeLa cells. J Biol Chem 1999;274(45):32122-32126. (Pubitemid 129503807)
51. Li X, Darzynkiewicz Z. Cleavage of Poly(ADP-ribose) polymerase measured in situ in individual cells: Relationship to DNA fragmentation and cell cycle position during apoptosis. Exp Cell Res 2000;255(1):125-132.
52. He J, Whitacre CM, Xue LY, Berger NA, Oleinick NL. Protease activation and cleavage of poly(ADP-ribose) polymerase: An integral part of apoptosis in response to photodynamic treatment. Cancer Res 1998;58(5):940-946.
53. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53(17):3976-3985.
54. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 2003;63(10):2645-2648. (Pubitemid 36605208)
55. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58(18):4055-4060. (Pubitemid 28440554)
56. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003;14(12):4835-4845. (Pubitemid 37484800)
57. Bonnett R, Martinez G. Photobleaching of compounds of the 5,10,15,20-Tetrakis(m-hydroxyphenyl)porphyrin Series(m-THPP, m-THPC, and m-THPBC). Org Lett 2002;4(12):2013-2016.
58. Strauss WS, Sailer R, Gschwend MH, Emmert H, Steiner R, Schneckenburger H. Selective examination of plasma membrane-associated photosensitizers using total internal reflection fluorescence spectroscopy: Correlation between photobleaching and photodynamic efficacy of protoporphyrin IX. Photochem Photobiol 1998;67(3):363-369.
59. Brasseur N, Ouellet R, La Madeleine C, van Lier JE. Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: Photodynamic activities and pharmacokinetics in tumour-bearing mice. Br J Cancer 1999;80(10):1533-1541.
60. Caruso JA, Mathieu PA, Reiners JJ Jr. Sphingomyelins suppress the targeted disruption of lysosomes/endosomes by the photosensitizer NPe6 during photodynamic therapy. Biochem J 2005;392(Pt 2):325-334. (Pubitemid 41796521)
61. Brunk UT, Dalen H, Roberg K, Hellquist HB. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic Biol Med 1997;23(4):616-626. (Pubitemid 27287345)
62. Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 2007;1776(1):86-107. (Pubitemid 47332075)
63. Liu X, Zou H, Slaughter C, Wang X, DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997;89(2):175-184. (Pubitemid 27199890)
64. Naito M, Nagashima K, Mashima T, Tsuruo T. Phosphatidylserine externalization is a downstream event of interleukin-1 beta-converting enzyme family protease activation during apoptosis. Blood 1997;89(6):2060-2066. (Pubitemid 27132122)
65. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391(6662):43-50. (Pubitemid 28079208)
66. Yu A, Byers DM, Ridgway ND, McMaster CR, Cook HW. Preferential externalization of newly synthesized phosphatidylserine in apoptotic U937 cells is dependent on caspase-mediated pathways. Biochim Biophys Acta 2000;1487(2-3):296-308.
67. Kessel D, Luo Y, Deng Y, Chang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1997;65(3):422-426. (Pubitemid 27158974)